Ensysce Biosciences (ENSC) EBIT (QoQ) (2018 - 2025)
Ensysce Biosciences (ENSC) EBIT (QoQ) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | Ensysce Biosciences | 927,304.90 | -3.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -113.71% |
| Jun 30, 2025 | 11.03% |
| Mar 31, 2025 | 44.99% |
| Dec 31, 2024 | -654.71% |
| Sep 30, 2024 | 132.97% |
| Jun 30, 2024 | -6.10% |
| Mar 31, 2024 | 41.60% |
| Dec 31, 2023 | -16.56% |
| Sep 30, 2023 | -18.02% |
| Jun 30, 2023 | 10.44% |
| Mar 31, 2023 | 58.69% |
| Dec 31, 2022 | -0.61% |
| Sep 30, 2022 | 12.64% |
| Jun 30, 2022 | -46.90% |
| Mar 31, 2022 | -139.33% |
| Dec 31, 2021 | 88.12% |
| Sep 30, 2021 | -3,992.61% |
| Jun 30, 2021 | 21.30% |
| Mar 31, 2021 | 52.05% |
| Dec 31, 2020 | -170.11% |